ESR1 and breast cancer: The primary objective of these studies was to determine whether tumoral ERα signaling, in addition to well-known proliferative effects that are not site-specific, could be driving osteolysis within the bone microenvironment, thus potentially explaining the greater proclivity of ER+ (vs. ER−) breast cancer cells to form clinically evident osteolytic BMET.